ESMO Gastrointestinal Cancers Congress | Conference

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

July 4th 2025

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC

July 3rd 2025

TACE plus atezolizumab and bevacizumab may represent effective option for untreated intermediate-to-high tumor burden unresectable HCC.

TTFields Plus Chemo Improves QOL, Delays Time to Pain Deterioration in Locally Advanced Pancreatic Adenocarcinoma

July 3rd 2025

The addition of TTFields to chemotherapy improved quality of life and delayed time to pain deterioration in locally advanced pancreatic cancer.

Nivolumab Plus Ipilimumab Improves HRQOL Vs Nivolumab Alone in MSI-H/dMMR mCRC

July 3rd 2025

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Perioperative Durvalumab/FLOT Does Not Diminish PROs in Resectable Gastric/GEJ Adenocarcinoma

July 3rd 2025

Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.

Dr O’Reilly on the Rapidly Evolving Role of Local Therapy in Metastatic Pancreatic Cancer

July 3rd 2025

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Dr Weinberg on the Efficacy of BXCL701 Plus Pembrolizumab in Pretreated, Metastatic PDAC

July 3rd 2025

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Dr Cheng on the Safety and Efficacy of Irpagratinib Plus Atezolizumab in Advanced HCC

July 3rd 2025

Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.

Givastomig Combo Shows Early Promise in CLDN18.2+ Gastric, Esophageal, GEJ Adenocarcinoma

July 2nd 2025

Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.

Invikafusp Alfa Generates Antitumor Activity in PD-(L)1–Resistant and –Naive, Antigen-Rich GI Tumors

July 2nd 2025

Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC

July 2nd 2025

Irpagratinib combined with atezolizumab was effective and safe in both treatment-naive and ICI-exposed advanced HCC with FGF19 overexpression.

Certepetide Plus Chemotherapy Shows ORR, PFS Benefits Over Placebo in Metastatic PDAC

July 2nd 2025

Certepetide plus gemcitabine and nab-paclitaxel was safe and effective in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs

July 2nd 2025

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer

July 8th 2024

Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.

Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer

July 2nd 2024

Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.

First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups

July 2nd 2024

Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.

IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

July 2nd 2024

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Mitazalimab/mFOLFIRINOX Is Tolerable, Generates Responses in Treatment-Naive mPDAC

July 2nd 2024

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer

July 1st 2024

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer

July 1st 2024

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.